Catalyst Wire Dossier Catalyst Wire Dossier

CA102N

· Holy Stone Healthcare Co., Ltd
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CA102N, covering 2023-09-15 to 2023-09-15. Get the full timeline:

Most recent: Clinical Trial Update: Phase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Relapsed and/or Refractory Metastatic Colorectal Cancer [Phase 2]

See pricing